GB0610868D0 - Treatment of pain - Google Patents

Treatment of pain

Info

Publication number
GB0610868D0
GB0610868D0 GBGB0610868.2A GB0610868A GB0610868D0 GB 0610868 D0 GB0610868 D0 GB 0610868D0 GB 0610868 A GB0610868 A GB 0610868A GB 0610868 D0 GB0610868 D0 GB 0610868D0
Authority
GB
United Kingdom
Prior art keywords
pain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0610868.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Allergan Inc
Original Assignee
Syntaxin Ltd
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd, Allergan Inc filed Critical Syntaxin Ltd
Priority to GBGB0610868.2A priority Critical patent/GB0610868D0/en
Publication of GB0610868D0 publication Critical patent/GB0610868D0/en
Priority to PCT/GB2007/002042 priority patent/WO2007138336A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0610868.2A 2006-06-01 2006-06-01 Treatment of pain Ceased GB0610868D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0610868.2A GB0610868D0 (en) 2006-06-01 2006-06-01 Treatment of pain
PCT/GB2007/002042 WO2007138336A2 (fr) 2006-06-01 2007-06-01 Traitement de la douleur

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610868.2A GB0610868D0 (en) 2006-06-01 2006-06-01 Treatment of pain

Publications (1)

Publication Number Publication Date
GB0610868D0 true GB0610868D0 (en) 2006-07-12

Family

ID=36694796

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0610868.2A Ceased GB0610868D0 (en) 2006-06-01 2006-06-01 Treatment of pain

Country Status (2)

Country Link
GB (1) GB0610868D0 (fr)
WO (1) WO2007138336A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
SG185338A1 (en) 2007-10-23 2012-11-29 Allergan Inc Methods of treating urogenital-neurological disorders using modified clostridial toxins
EP2334315B1 (fr) 2008-09-03 2023-01-18 NoNO Inc. Agents et méthodes de traitement de la douleur
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
WO2006059105A2 (fr) * 2004-12-01 2006-06-08 Health Protection Agency Conjugués protéiques non cytotoxiques

Also Published As

Publication number Publication date
WO2007138336A3 (fr) 2008-12-11
WO2007138336A2 (fr) 2007-12-06

Similar Documents

Publication Publication Date Title
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
HK1207578A1 (en) Treatment of synucleinopathies
GB0602178D0 (en) Therapeutic treatment
EP1982660A4 (fr) Endoscope de traitement
IL198663A0 (en) Tissue treatment methods
IL197315A0 (en) Treatment of cancer
EP2049139A4 (fr) Traitement de tumeurs exprimant ras
HK1255227A1 (zh) 疼痛治療
GB0608655D0 (en) Therapeutic Treatment
ZA200806808B (en) Treatment of stressed patients
EP1968591A4 (fr) Traitement de formes de synucleinopathie
IL213703A (en) Compounds for the treatment of pain and other diseases
EP2007790A4 (fr) Composes et procedes destines au traitement de la douleur
GB0610909D0 (en) Therapeutic treatment
GB0610868D0 (en) Treatment of pain
IL202639A0 (en) Treatment of neuropathic pain
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0723100D0 (en) Treatment of HFnEF
EP2124950A4 (fr) Traitement d'une douleur avec de la naloxone
EP2164494A4 (fr) Procédés de traitement
GB0618060D0 (en) Treatment of polyamides
GB0616450D0 (en) Treatment of pain
GB0623740D0 (en) Treatment of disease
GB0610376D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)